ENANTA PHARMACEUTICALS INC (ENTA)

Notable Two Hundred Day Moving Average Cross - ENTA

Enanta Pharmaceuticals Announces Data Presentation at ESCMID Global 2024

Enanta Pharmaceuticals to Participate at Leerink Partners Global Biopharma Conference

Enanta Pharmaceuticals Breaks Above 200-Day Moving Average - Bullish for ENTA

Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET

Enanta Pharmaceuticals to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

Commit To Purchase Enanta Pharmaceuticals At $10, Earn 33.2% Annualized Using Options

Enanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal First Quarter Ended December 31, 2023

Enanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2024 Outlook at the 42nd Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Enanta Pharmaceuticals files for a $150M mixed shelf offering (NASDAQ:ENTA)

Enanta Pharmaceuticals filed a prospectus for a mixed shelf offering to raise up to $150M, but the document is not an offer to sell the securities.

Enanta Pharmaceuticals to Participate at Evercore ISI HealthCONx Conference

Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET

Enanta Pharmaceuticals to Host Conference Call on November 20 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Fourth Quarter and Full Year Ended September 30, 2023

Commit To Purchase Enanta Pharmaceuticals At $7.50, Earn 16.3% Annualized Using Options

Enanta Pharmaceuticals is Now Oversold (ENTA)

Enanta Pharmaceuticals to Host Virtual Key Opinion Leader Event to Discuss Advances in the Treatment Landscape for Respiratory Syncytial Virus (RSV) and its Proprietary RSV Pipeline

Enanta Pharmaceuticals Becomes Oversold (ENTA)

Enanta Pharmaceuticals to Present Data for EDP-323, its Oral, Once-Daily, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at the 9th ESWI Influenza Conference

Enanta Pharmaceuticals to Present Data for EDP-938, its Oral, Once-Daily, N-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2023

Enanta Pharmaceuticals is Now Oversold (ENTA)

Airbnb, Blackstone Rise On News They'll Join S&P 500 Index

ABNB and BX will join Sept. 18 as part of a quarterly rebalancing.

Enanta Pharmaceuticals to Participate in Investor Conferences in September

JP Morgan cuts Enanta to neutral, cites extended timelines for key drugs (ENTA)

JP Morgan has downgraded Enanta Pharmaceuticals (ENTA) to neutral, citing extended commercialization timelines for its COVID-19 and RSV treatments. Read more here.

Jefferies cuts Enanta to hold, cites concerns about COVID-19 drug (ENTA)

Jefferies has downgraded Enanta (ENTA) to hold, citing concerns that the company won't be able to find a commercial partner for its COVID-19 treatment EDP-235. Read more here.

Why Shares of Enanta Pharmaceuticals Are Dropping Tuesday

The company saw a slight revenue decline in its fiscal 2023 third-quarter earnings report.